Correction to "Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study". . Cancer 2025;131:e35933.

Read + Share

Amedeo Smart

Independent Medical Education